Recently William Haseltine wrote an excellent article on Forbes regarding ACE2 research and the development of therapeutics for SARS-Cov2. The article includes a link to research performed by Cyrus scientists Erik Procko …

Date:  Thursday, February 3, 2022 Time:  2pm ET / 11am PT Duration:  1 Hour Sign up here to go to the webinar Improving the discovery of novel drugs with artificial intelligence Last year, Toronto-based Deep …

https://www.nature.com/articles/s41589-021-00965-6

SEATTLE, WA – (BUSINESS WIRE) – Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale parallel protein screening, today announced that …

SEATTLE, WA December 6, 2021 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and …

– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination …